Multi-ancestry GWAS of diarrhea during acute 3 SARS-CoV2 infection identifies multiple novel loci and contrasting etiological roles of irritable bowel syndrome subtypes Ninad S. Chaudhary¹, Catherine H. Weldon¹, Priyanka Nandakumar¹, Janie F. Shelton², 23andMe Research Team¹, Michael V. Holmes^{1*}, Stella Aslibekyan1* 13 Affiliations: 123andMe, Inc., Sunnyvale, CA; 2 Bristol Myers Squibb, Inc. 15 * joint senior authors

35 ABSTRACT

61

36 37 A substantial proportion of acute SARS-CoV2 infection cases exhibit gastrointestinal 38 symptoms, yet the genetic determinants of these extrapulmonary manifestations are 39 poorly understood. Using survey data from 239,866 individuals who tested positively for 40 SARS-CoV2, we conducted a multi-ancestry GWAS of 80,289 cases of diarrhea 41 occurring during acute COVID-19 infection (33.5%). Six loci (CYP7A1, LZFTL1--42 CCR9, TEME182, NALCN, LFNG, GCKR) met genome-wide significance in a 43 trans-ancestral analysis. The top significant GWAS hit mapped to the CYP7A1 locus, 44 which plays an etiologic role in bile acid metabolism and is in high LD (r^2 = 0.93) with the 45 SDCBP gene, which was previously implicated in antigen processing and presentation 46 in the COVID-19 context. Another association was observed with variants in the 47 LZTFL1-CCR9 region, which is a known locus for COVID-19 susceptibility and severity. 48 PheWAS showed a shared association across three of the six SNPs with irritable bowel 49 syndrome (IBS) and its subtypes. Mendelian randomization showed that genetic liability to IBS-diarrhea increased (OR=1.40,95%,CI[1.33-1.47]), and liability to IBS-constipation 51 decreased (OR=0.86, 95%CI[0.79-0.94]) the relative odds of experiencing COVID-19+ 52 diarrhea. Our genetic findings provide etiological insights into the extrapulmonary 53 manifestations of acute SARS-CoV2 infection. 54 55 56 57 58 59 60

62 INTRODUCTION

Diarrhea is a common extrapulmonary gastrointestinal (GI) symptom of acute COVID-19. Retrospective studies estimate that the prevalence of COVID-19 related diarrhea (defined herein as COVID-19+ diarrhea) varies between 7% and 18% for population based and hospital based cohorts, respectively 1-3. There is growing evidence that SARS-CoV2 tropism (the ability of a virus to infect multiple cell types) in gastrointestinal tissues may lead to alteration of gut microbiota 4,5 and persistence of virus in the gastrointestinal system, which is associated with a higher risk of post-acute sequelae such as long COVID6. SARS-CoV2 RNA can be detected in fecal samples of COVID-19+ patients up to 4 months after acute infection, with fecal viral RNA detectable for longer durations among individuals with COVID-19+ diarrhea as compared to those without diarrhea⁷. Yet, the gastrointestinal symptoms of SARS-CoV2 positive individuals have not been studied in GWAS.

The SARS-CoV virus enters the body via angiotensin-converting enzyme 2

76 (ACE2) and co-receptor transmembrane protease serine 2 (TMPRSS2)⁸ receptors that

77 are predominantly expressed in the lung. ACE2 and TMPRSS2 receptors are also

78 expressed in gastric mucosal cells, enterocytes, and colonocytes⁹, making the GI tract a

79 potential extrapulmonary site of SARS-CoV2 infection. SARS-CoV2 RNA and viral

80 proteins were detected in epithelial cells from intestinal biopsies of COVID-19 patients

81 with acute infection¹⁰. In postmortem data from 13 patients, SARS-CoV2 subgenomic

82 RNA was detected in the small intestinal tissues from eight patients, indicative of viral

83 replication¹¹. It is not clear whether GI symptoms are the direct consequence of

84 SARS-CoV2 infection of intestinal cells or due to a systemic immune-inflammatory

response. GWAS can provide insights into the genetic architecture of disease and shed light on potential etiological mechanisms. To date, no GWAS studies of COVID-19+ diarrhea have been conducted. We sought to bridge this gap by conducting a GWAS of self-reported diarrhea symptoms among 239,866 COVID-19 test positive 23ndMe research participants.

90

91 RESULTS

Of the individuals who self-reported testing positive for SARS-CoV2, 33% 92 93 reported diarrhea as a symptom (N=80,289 cases of COVID-19+ diarrhea / 239,866 94 acute COVID-19 cases who tested positive). Among 80,289 COVID-19+ diarrhea cases, 95 the vast majority reported diarrhea symptoms at baseline (N=79,361 cases) with a few 96 individuals reporting diarrhea at 1 month (N=313 cases), 2 months (N=346 cases), or 3 97 months of follow up (N=269 cases). Women accounted for the majority of the survey 98 participants (71.1% of COVID-19+ diarrhea cases and 65.4% of controls), and were 99 more likely to experience COVID-19+ diarrhea than men (adjusted OR[95%CI] =1.29[1.27,1.31]). Compared to those with COVID-19+ who didn't experience diarrhea, individuals with COVID-19+ diarrhea were younger, more likely to be of non-European 102 ancestry, and to have diabetes, depression, and high triglyceride levels (**Table 1**). 103 Individuals of East Asian (adjusted OR[95%CI]=0.85[0.79,0.94]) or African American 104 (adjusted OR [95%CI]=0.92[0.88,96]) ancestry had lower relative odds of reporting 105 diarrhea compared to those of European ancestry, whereas Latinx individuals were at 106 higher relative odds of reporting diarrhea (adjusted OR[95%CI]=1.21[1.09,1.14]). Those 107 reporting COVID-19+ diarrhea were more than twice as likely to be hospitalized during

the acute infection (6.6% in COVID-19+ diarrhea cases vs 3.0% in COVID-19+ controls; corresponding to an adjusted relative odds of 2.56; 95%CI: 2.46, 2.57) and were more likely to have severe respiratory disease (10.2% in COVID-19+ diarrhea cases vs 4.8% in COVID-19+ diarrhea controls; adjusted relative odds of 2.38; 95%CI: 2.30, 2.46) after adjusting for age, sex, and ancestry. Furthermore, those with COVID-19+ diarrhea had twice the odds of subsequently experiencing long COVID (43% in COVID-19+ diarrhea cases vs 23% in COVID-19+ diarrhea controls; adjusted relative odds of 2.53; 95%CI: 2.46, 2.61) and of long COVID impacting daily living activities (16% of COVID-19+ diarrhea cases vs 9.6% of COVID-19+ diarrhea controls; adjusted relative odds of 2.27; 117 95%CI: 2.21, 2.34).

118

GWAS: We conducted GWAS within each of European, African American, Latinx, East Asian, and South Asian ancestry groups, and then meta-analyzed across ancestries using fixed effect modeling. Individuals of European ancestry contributed to the sample size to multi-ancestry analysis, with African-Americans contributing 4%, Latinx 18%, East Asians 2%, and South Asians 1%. We identified six distinct loci associated with COVID-19+ diarrhea in multi-ancestry analysis (Table 2, Figure 1). The associations of index variants were statistically significant at baseline but not at the following time points (1 and 3 months after onset of acute infection) likely owing to lack of statistical power (Supplementary Table 1). The top statistically significant index variant at chr8q12.1 (rs10504255) is situated in the intergenic region of genes UBXN2B and CYP7A1, located 4kb upstream of the CYP7A1 gene. rs10504255 (A/G with G being the effect allele) was associated with COVID-19+ diarrhea with OR[95% CI] =

131 0.94[0.92,0.95], p= 2.6x10⁻¹⁶. The credible set from multi-ancestry analysis contained 16
132 variants covering a 100.4-kilobase(kb) region (**Supplementary Figure 1**). The
133 association was primarily driven by individuals of European ancestry (p = 1.08 X 10⁻¹⁴)
134 as compared to other ancestries (**Supplementary Table 2**). In the analysis of
135 expression quantitative trait loci (eQTL), rs10504255 was found to be in high LD with a
136 variant (rs9297994) associated with *CYP7A1* expression in the thyroid gland (p =
137 8.1X10⁻⁹) and a variant (rs8192870) associated with expression of a nearby gene
138 (*SDCBP*, r²=0.94, p=9.9X10⁻¹⁰) in left ventricular myocardium (**Supplementary Table**139 3)¹². Previous studies have shown *SDCBP* expression to correlate with *HLA-DPB1*140 expression in normal lung tissue ¹³. The variant rs35044562 (alleles A/G with G being
141 the effect allele) on chr3p21.31 lies in the intergenic region of *LZTFL1* and *CCR9*142 (**Supplementary Figure 2**). *LZTFL1* is widely expressed in ciliated epithelial cells in
143 lungs ¹⁴. Additional genes in this regulatory locus include *CCR9*, primarily expressed in
144 immune cells, and *SLC6A20* in the gastrointestinal tract.

145

The variants, rs75683620, at chr2q12.1 (*TMEM182*, alleles A/G with G being the effect allele, p=5.0 X 10⁻⁰⁹, **Supplementary Figure 3**), rs536843010 at chr13q33.1 (*NALCN*, alleles A/C with C being the effect allele, p=9.8X10⁻⁰⁹, **Supplementary Figure 4**), and rs13245319 at chr7p22.3 (*GRIFIN--[]-LFNG*, alleles C/T with T being the effect allele, p = 1.79X10⁻⁰⁸, **Supplementary Figure 5**) were not associated with functional effects in eQTL or pQTL analysis. These variants are relatively rare in the studied populations, except for rs75683620 (MAF= 0.042) among individuals of African

153 American ancestry. These variants were monomorphic among East and South Asians,
154 meaning that data from these populations did not contribute to the meta-analysis.

155

We also identified an association at chr2p23.3 (*GCKR*, rs1260326, alleles C/T with T being the effect allele, **Supplementary Figure 6**) that was genome-wide significant in the meta-analysis (p = 1.98×10^{-08}) and in the European population (p = 1.59×10^{-08}). rs1260326 is a missense variant that is also in high LD with eQTLs for other nearby genes across multiple tissues, including kidney tubules (eQTL gene = NRBP1, p= 1.00×10^{-07}), CD4+ T cells (eQTL gene= 1.00×10^{-07}), and liver (eQTL gene= 1.00×10^{-07}), and liver (eQTL gene= 1.00×10^{-07}) (Supplementary Table 3d) significant from blood plasma within 500kb with r² > 0.8 of multiple pQTLs based on data from blood plasma 1.00×10^{-07} 0 (Supplementary Table 3b) significant associated with multiple traits significant in the effect alleles C/T and in the European population.

167

Association with COVID-19 measures: To explore the specificity of these genetic variants with COVID-19+ diarrhea vs COVID-19 severity, we examined the association of the lead variants with COVID-19 susceptibility and COVID-19 severity measures. The variant, rs3504462 (A/G with G as the risk allele), on chr3p21.31 was associated with COVID-19 test positivity (p = 1.1X 10⁻⁰⁵) and acute COVID-19 infection leading to hospitalization (p = 1.1X10⁻⁵⁶) or severe respiratory disease (p = 7.1X10⁻⁶⁹). In contrast, the other variants were not associated with any of these COVID-19 measures (Supplementary Table 4). Thus, with the exception of the chr3p21.31 locus, the

176 genetic signals of COVID-19+ diarrhea are likely to drive their effects through
177 mechanisms unrelated to COVID-19 severity.

178

PheWAS: To characterize these loci, we performed a phenome-wide association study (PheWAS) across 1,482 phenotypes available in the 23andMe, Inc. database in the population of European ancestry. PheWAS results for variants are presented in Supplementary Table 5. Among phenotypes associated with rs10504255, the strongest associations were with high cholesterol (p = 7.53 X 10⁻¹⁷²) and IBS-D (p = 5.31 X 10⁻¹³⁴). Other associated phenotypes were cardiometabolic traits such as type 2 diabetes, high blood pressure and statin use (Supplementary Table 5a). In addition to the measures of COVID-19 susceptibility and severity, the rs35044562 variant was also associated with autoimmune conditions (Hashimoto's disease, celiac disease) (Supplementary Table 5b). PheWAS for rs1260326 identified associations with lipid profile, allergic conditions, and blood glucose levels (Supplementary Table 5c). The main associations for rs1324319 were IBS, kidney stones, and obesity (Supplementary Table 5d). No traits were associated with rs75683620 or rs536843010 at the

193

Focusing specifically on gastrointestinal disorders among outcomes constituting
the PheWAS analysis, and orienting effect alleles to a higher risk of COVID-19+
diarrhea, four SNPs (rs10504255, rs1260326, rs35044562 and rs13245319)
demonstrated associations with GI traits in addition to COVID19+ diarrhea (**Figure 2**),
line including IBD (both ulcerative colitis and Crohn's disease), celiac disease, lactose

intolerance and IBS. Directionally consistent associations with higher risks of IBS (for rs10504255, rs1260326 and rs13245319) and IBS-D (rs10504255, rs1260326) were identified whereas a directionally opposite association between COVID-19+ diarrhea and IBS-C (rs10504255) was found (**Supplementary Figure 7**).

203

Mendelian randomization: Given that a common association on PheWAS 204 205 across three of the six lead variants was an association with IBS and IBS subtypes, and 206 to more fully characterize the translational relevance, we investigated the potential 207 causal relationship between genetic liability to IBS-C and IBS-D and COVID-19+ 208 diarrhea through Mendelian randomization (MR). Using a genetic instrument consisting 209 of 180 SNPs for IBS-D, we identified strong evidence of a potential causal effect of 210 liability to IBS-D and risk of COVID-19+ diarrhea (OR=1.40,95%,CI[1.33-1.47] from 211 random-effects IVW modeling). Steiger filtering removed three SNPs with minimal 212 impact to the IVW MR estimate (OR=1.39,95% CI[1.32-1.46]). These causal estimates 213 persisted or strengthened on robust MR approaches: weighted median provided 214 findings that were largely similar to IVW MR (OR=1.37,95%,CI[1.28-1.47]), with the 215 estimate from MR Egger yielding a stronger predicted causal effect 216 (OR=2.02,95%,CI[1.76-2.32]) (Figure 3, Supplementary Figure 8). The intercept from 217 MR Egger regression was statistically significantly different from zero [$\beta(SE)$ = 218 -0.121(0.002); p= 1.74 X 10⁻⁰⁷], indicating presence of directional pleiotropy 219 (Supplementary Table 6).

The MR estimates for IBS-C were directionally opposite (0.86, 95%CI[0.79-0.94]; IVW modeling) to those of IBS-D. MR estimates remained unchanged after removing

one SNP following Steiger filtering (OR=0.89,95% CI[0.82-0.96]). Robust MR analyses provided consistent findings although the magnitude of the predicted causal estimate was further from the null on MR-Egger; the intercept from MR Egger was $\beta(SE) = 0.008(0.008)$ with a p-value of 0.31.

Given partial overlap of individuals contributing to GWAS (**Supplementary Figure 9**), we conducted a sensitivity analysis using non-overlapping samples which yielded nearly identical findings (**Supplementary Table 7**).

229

230 DISCUSSION

In this era of widespread documentation of SARS-CoV2 effects on human health, there is an important gap in understanding extrapulmonary symptoms. In this study, we address this gap by utilizing a direct-to-consumer research platform contributing data on 80,289 cases of diarrhea during acute SARS-CoV2 infection. We identified three loci (CYP7A1, LZTFL1-CCR9, and GCKR) that have plausible biological mechanisms of action. Except for LZTFL1-CCR9, none of these genetic signals was associated with COVID-19 severity, indicating the role of distinct biological pathways. We further observed a consistent association of top variants at the CYP7A1, GCKR, and LFNG loci with IBS and IBS sub-types. Genetic liability towards IBS-D increased the risk of having COVID-19+ diarrhea, while genetic liability for IBS-C reduced this risk. These results highlight the role of genetic predisposition to preexisting comorbidities in the

The top significant locus in our study, mapped to CYP7A1, encodes a member of 244 245 the cytochrome p450 enzyme family, which has an important role in the bile acid 246 synthesis pathway 22. Polymorphisms at this locus are associated with defects in bile 247 acid synthesis, affecting enzymatic activity of cholesterol 7-alpha hydroxylase and 248 resulting in bile acid diarrhea. On eQTL analysis, we observed rs10504255 to be in high 249 LD with a variant (rs8192870) associated with expression of a nearby gene (SDCBP, 250 r2=0.93,p=9.9X10-10) in the left ventricular myocardium ¹². SDCBP is also expressed in 251 the intestine, as well as in lung cancers including adenocarcinoma and small cell 252 carcinoma¹². A recent single-cell RNA sequencing study observed that SDCBP likely 253 plays a role in antigen processing and presentation in bronchial epithelial cells from 254 COVID-19 patients, 13 with SDCBP expression correlating with HLA-DPB1 expression in 255 normal lung tissues ¹³. HLA-DPB1 represents a critical immune mechanism as it is 256 expressed on antigen presenting cells that participate in eliciting an immune response 257 to foreign viral peptides. Overall, these findings suggest a possible role of bile acid 258 synthesis pathways and/or the immune system in COVID-19+ diarrhea.

259

LZTFL1, SLC6A20 and CCR9 are part of the chemokine receptor gene cluster at chr3p21, previously identified as COVID-19 susceptibility and severity loci ^{23–26}. LZTFL1 at this locus likely regulates viral response pathways by inhibiting the transcription factors that reduce levels of ACE2 and TMPRSS ¹⁴. SLC6A20 is extensively expressed in the gastrointestinal tract, where it forms a complex with ACE2 receptors, facilitating viral entry ²⁴. CCR9 is expressed in T-lymphocytes of the small intestine and colon,

mechanisms may contribute to pathophysiology of diarrheal disease during acute SARS-CoV2 infection.

269

PheWAS characterization of top GWAS loci identified directionally opposite
signals with IBS subtypes. Genetic liability to IBS-D increased, and liability to IBS-C
decreased the probability of experiencing diarrhea during the acute phase of
SARS-CoV2 infection. These effects could be driven by genetic liability to frequency of
bowel motions, modifying the manifestation of diarrhea in the context of an acute
infection affecting the GI tract. An alternative explanation might be that individuals at
greater liability to IBS-D have altered bowel characteristics that make them more
susceptible to GI infection and diarrhea in the context of acute COVID-19 infection. For
susceptible to GI infection and diarrhea in the context of acute COVID-19 infection. For
microbiome which could play a role in susceptibility to COVID-19+ diarrhea ^{28,29}.

280

The remaining significantly associated genetic loci do not have direct evidence of involvement in the gastrointestinal tract or SARS-CoV2 infection. *GCKR* is a pleiotropic locus associated with C-reactive protein, fasting plasma glucose levels, and blood cell traits ^{21,30}. *GCKR*-mediated effects are driven via regulation of glucokinase enzymes that control the first step of glycolysis. The gene *TMEM182* (rs75683620) at chr2q12.1 has been associated with central obesity and systolic blood pressure in Asian populations The gene is expressed in heart tissue and regulates its effects via tumor necrosis factor-alpha ³². The *NALCN* gene (rs536843010) at chr13q33.1 contributes to

membrane potential via voltage independent, nonselective cation channels ³³. It accordingly is involved in control of muscular activity, respiration, and circadian rhythms ³³. The function of the LFNG gene (rs13245319) is regulated via the notch signaling pathway ³⁵. The notch pathway maintains the homeostasis of multiple tissues and thus plays a role in cancerous growth, including colorectal adenocarcinoma ^{36,37}. These associations require independent validation and additional functional investigations to identify any biological relevance to acute COVID-19+ diarrhea.

297

Our study has several limitations. European participants contributed 75% of our 298 299 sample size, so the statistical power to detect genetic associations was driven largely by 300 this group. While the large sample size is an important strength for our study, replication 301 of the GWAS and MR findings by other studies would establish reproducibility and 302 strengthen the findings. Diarrhea cases reported 2 to 3 months after acute infection 303 might be misattributed to COVID-19 as opposed to another source. However, the vast 304 majority (99%) of our cases of COVID-19+ diarrhea occurred at the same time as the 305 diagnosis of COVID-19. Furthermore, individuals with genetic liability to IBS-D may 306 have misattributed diarrhea at the time of acute COVID-19 to the infection as opposed 307 to their underlying IBS-D. Refuting this hypothesis is our observation that individuals 308 with IBS-C had a lower relative odds of experiencing COVID-19+ diarrhea, which 309 collectively may be indicative of an acute infection operating on top of a background 310 genetic liability to IBS-D or IBS-C, with liability to either IBS-D or IBS-C influencing the 311 probability of experiencing COVID-19+ diarrhea in a potentially etiological way. Finally, 312 the MR-Egger intercept for IBS-D indicated evidence of directional pleiotropy. However,

the pleiotropy-corrected point estimate from MR-Egger was larger (OR=2.02) than that derived from IVW (OR=1.40), making the latter a conservative estimate.

315

In conclusion, the first GWAS of COVID-19+ diarrhea in an ancestrally diverse,
large-scale population-based cohort identifies biologically relevant signals associated
with bile acid synthesis and immune function, including antigen presenting and cytokine
signaling. By virtue of limiting our study to COVID-19+ individuals, we infer and
substantiate empirically that all but one of the identified loci are specific to COVID-19+
diarrhea rather than markers of susceptibility to SARS-CoV2 infection. Finally, we
provide causal evidence in support of the etiological role of liability to chronic intestinal
disorders and gastrointestinal symptoms during acute infection.

324 METHODS

325 Study Population

Participants older than 18 years old were recruited for 23andMe COVID-19 study
from April 2020 using email-based surveys. The surveys were distributed to 6.7 million
individuals who provided informed consent and volunteered to participate in the
research online, under a protocol approved by the external AAHRPP-accredited IRB,
thical & Independent (E&I) Review Services. As of 2022, E&I Review Services is part
for Salus IRB. Recruitment was initially geo-targeted to capture cases as the outbreak
spread across the U.S and was continued later on to recruit additional participants. We
included only those participants who had responded to COVID-19 survey and provided
symptom information by August, 2023 for this study. Details on diagnosis, testing, and

symptoms of COVID-19, as well as markers of severity and relevant comorbid conditions were collected via one baseline and three follow-up surveys administered three months apart. Full details of the data collection procedures for this study have been described previously³⁸.

339

340 Phenotype

Using the survey information, we defined the diarrhea outcome among
individuals who self-reported testing positive for COVID-19. Participants were asked the
question whether they experienced any of the following symptoms to which they could
select as many as needed from the following list of responses: 'muscle or body aches/
statigue/ dry cough/ sore throat/ coughing up of sputum or phlegm (productive cough)/
statigue/ dry cough/ sore throat/ coughing up of sputum or phlegm (productive cough)/
statightness in upper chest/ diarrhea/ nausea or vomiting/ sneezing/ loss of appetite/ runny
shall nose/ headache/ intensely red or watery eyes'. Participants who reported experiencing
shall diarrhea symptoms at baseline or follow-up surveys were identified as cases and those
should not experience diarrhea were controls. The analytical dataset included
unrelated individuals with non-missing information on COVID-19+ diarrhea and
static covariates included in GWAS analyses (N=239,866).

353

354 Genotyping

DNA extraction and genotyping were performed on saliva samples by Clinical
Laboratory Improvement Amendments-certified and College of American
Pathologists-accredited clinical laboratories of Laboratory Corporation of America.

358 Samples were genotyped across the five genotyping platforms and imputed using three 359 combined independent reference panels: the publicly available Human Reference 360 Consortium (HRC), and UK BioBank (UKBB) 200K Whole Exome Sequencing (WES) 361 reference panels and the 23andMe reference panel, which was built by 23andMe using 362 internal and external cohorts. Each genotyping platform was imputed and phased 363 separately. The final genotyped variants included 1,469,237 variants and the final 364 imputation panel included a total of 99,675,338 variants (90,582,19 SNPs and 365 9,093,144 indels). The variant quality control statistics were computed independently 366 with each phasing panel and genotyping platform. We removed variants with low 367 imputation quality (r2 < 0.5 averaged across batches or a minimum r2 < 0.3) or 368 evidence of differences in effects across batches. For genotyped variants, we removed 369 variants only present on our V1 or V2 arrays (due to small sample size) that failed a 370 Mendelian transmission test in trios (P < 10⁻²⁰), failed a Hardy–Weinberg test in individuals of European ancestry (P < 10^{-20}), failed a batch effect test (ANOVA P < 10^{-50}) 372 or had a call rate <90%. For imputed variants in HRC panel, following filters were used: 373 singletons were excluded, multi-allelics were split into bi-allelic variants (with bcftools), 374 variants with >20% missingness were removed, variants with minor allele count == 0 375 were removed, and variants with inbreeding coefficient < -0.3 (high heterozygosity) were 376 removed.

377

378 Ancestry Classification

379 Ancestries in the 23andMe database are determined using a classifier algorithm based 380 on analysis of local ancestry 39. Phased genotyped data were first partitioned into

381 windows of about 300 SNPs and a support vector machine (SVM) approach was 382 applied within each window to classify individual haplotypes into one of 45 worldwide 383 reference populations. The SVM classifications are then fed into a hidden Markov model 384 (HMM) that accounts for switch errors and incorrect assignments, and gives 385 probabilities for each reference population in each window. Finally, we used simulated 386 admixed individuals to recalibrate the HMM probabilities so that the reported 387 assignments are consistent with the simulated admixture proportions. We aggregated 388 the probabilities of the 45 reference populations into six main ancestries (European, 389 African-American, Latinx, East Asian, South Asian, Middle Eastern) using a 390 predetermined threshold 39. African Americans and Latinx were admixed with broadly 391 varying contributions from Europe, Africa and the Americas. No single threshold of 392 genome-wide ancestry could effectively discriminate between African Americans and 393 Latinx. However, the distributions of the length of segments of European, African and 394 American ancestry are very different between African Americans and Latinx, because of 395 distinct admixture timing between the three ancestral populations in the two ethnic 396 groups. Therefore, we trained a logistic classifier that took the participant's length 397 histogram of segments of African, European and American ancestry, and predicted 398 whether the customer is likely African American or Latinx.

399

400

401 GWAS Analysis

To obtain unrelated participants for our GWAS analyses, individuals were included such that no two individuals shared more than 700 cM of DNA identical by

404 descent. We excluded approximately 1.80% of the sample to obtain such a set of 405 unrelated individuals. If a case and control were identified as having at least 700cM of 406 DNA IBD, we retained the case from the sample. We conducted association analysis 407 using logistic regression, assuming additive allelic effects and adjusting for age, 408 age-squared, sex, sex-age interaction, genotyping platform variables and ten principal 409 components to account for residual population structure. We combined the GWAS 410 summary statistics from both genotyped and imputed data. When choosing between 411 imputed and genotyped GWAS results, we favored the imputed result, unless the 412 imputed variant was unavailable or failed quality control. The summary statistics were 413 adjusted for inflation using genomic control when the inflation factor was estimated to be 414 greater than one (λ = 1.029, 1.037, 1.024, 1.042 and 1.071 within the European, Latinx, 415 African American, East Asian and South Asian ancestry GWAS, respectively). We 416 defined the region boundaries by identifying all SNPs with P < 10⁻⁵ within the vicinity of a 417 genome-wide significance association and then grouping these regions into intervals so 418 that no two regions were separated by less than 250 kb. We considered the SNP with 419 the smallest P value within each interval to be the **index variant**. Within each region, 420 we calculated a credible set of variants using the method of Maller et al 2021 $^{\rm 40}$.

421

We conducted the GWAS analysis separately in five population cohorts

(European, Latinx, African-Americans, East Asian, and South Asian ancestry). We then

meta-analyzed the GWAS summary statistics of these populations using an inverse

variance fixed effect model. For this approach, we included variants that had at least 1%

minor allele frequency in the pooled sample and minor allele count > 30 within each

subpopulation. The resulting meta-analyses were also adjusted for inflation (λ = 1.001) using genomic control.

429

430 PheWAS Analysis

We conducted phenome-wide associations (PheWAS) on the index variants from loci that were statistically significant on multi-ancestry analysis. The PheWAS analysis was limited to data from participants of European ancestry. We used data on 1,482 phenotypes that were available in the 23andMe research database. Data on these phenotypes were collected using online survey-based questionnaires completed by the participants at the time of recruitment in 23andMe genetic database. PheWAS analysis was performed, adjusting the association between each phenotype and variant of interest for age, sex, and the first five principal components of ancestry. We reported the associations that met the statistical threshold of significance after correcting for multiple testing (p < 0.05 / (1,482*6)= 5.62 X 10⁻⁰⁶).

441

442 Mendelian Randomization

Because PheWAS highlighted a shared association with irritable bowel syndrome (IBS) and IBS subtypes, we explored whether there was a potential causal role of genetic liability to IBS subtypes and COVID-19+ diarrhea by conducting two-sample Mendelian randomization (MR) using the *twosampleMR* R package 41. The initial MR analysis included overlapping samples of IBS subtypes and COVID-19+ diarrhea in the European population. We focused on the IBS subtypes of diarrhea (IBS-D) and constipation (IBS-C). We first obtained separate genetic instruments for IBS-C and

450 IBS-D from genome-wide significant SNPs for the relevant endpoint that had a minor
451 allele frequency of more than 0.01. We then identified variants with the smallest p-value
452 (index variants) by defining the regions of significant association based on genome-wide
453 significant SNPs as described above. These index variants were included in the genetic
454 instrument of the relevant phenotype (IBS-C or IBS-D). The genetic instrument for
455 IBS-D included 180 SNPs (mean F-statistic per SNP=50.2) and for IBS-C included 52
456 SNPs (mean F-statistic per SNP=43.6). Using the summary statistics of SNPs with
457 IBS-D and IBS-C adjusted for age, sex, and principal components of ancestral structure
458 in the European population, we then fitted random effects inverse variance weighted
459 (IVW) models and obtained MR estimates of IBS subtypes on COVID-19+ diarrhea. To
460 test the veracity of the findings, we used Steiger filtering and robust MR approaches
461 including weighted median, and MR-Egger method 41-43. As a sensitivity analysis, we
462 repeated MR analysis between IBS subtypes and COVID-19+ diarrhea after excluding
463 the overlapping samples between them.

464

465 Functional Annotation of GWAS Index Variants

466

To perform variant-to-gene mapping, hypotheses of functionally relevant genes
are generated by annotating the strongest associations (index variants) with nearby
functional variants. The mapping is computed by searching functional variants within
functional variants within a filter of linkage disequilibrium r2 > 0.8. Functional
variants for mapping include coding variants (annotated by the Ensembl Variant Effect
Predictor (VEP) v109 44), eQTLs, and pQTLs. The eQTL annotation resources consist of
a comprehensive collection of standardized variants impacting gene expression in
various tissues obtained from publicly available datasets

475 processed by the 23andMe eQTL pipeline. The pQTL annotation resources similarly 476 include a collection of curated protein QTLs from relevant public datasets ^{19,20}. 477 eQTL discovery. eQTL calling was performed with one of two versions of 23andMe 478 pipelines, depending on the dataset in question (Supplementary File). The first pipeline 479 used FastQTL 49 in permutation mode, restricting all tests to variants within a window 480 defined to be 1Mbp up- or downstream of a given gene's transcription start site (TSS) 481 (Supplementary File Table 1). Variants tested were single nucleotide polymorphisms 482 with an in-sample MAF ≥ 1%, to avoid errors in detection or mapping of larger genetic 483 variants in cross-ancestry comparisons, and models were adjusted for age (if available), 484 sex, probabilistic estimation of expression residuals (PEER) factors 50, genetic PCs, and 485 per-dataset covariates. For each gene, the index variant was identified by the minimal 486 permutation p-value. eQTLs were called then on lead variants if they passed a 5% FDR 487 filter using Storey's q-value 51 methodology. Conditional eQTLs were identified via 488 FastQTL's permutation mode, by using each eQTL as an additional covariate in the 489 model for a given gene. The lead conditional eQTL for all genes were again FDR 490 controlled at 5%, and a maximum of 10 conditional steps were run. Finally, for a set of 491 conditional eQTLs for a given gene, a joint model was fit, and the final eQTL callset 492 consisted of those eQTLs whose joint model test passed a 5% FDR filter. eQTLs were 493 only called for genes classified as one of 'protein coding', 'miRNA', 'IG C gene', 494 'IG D gene', 'IG J gene', 'IG V gene', 'TR C gene', 'TR D gene', 'TR J gene', 495 'TR V gene' as defined in GENCODE⁵². The second version of the 23andMe pipeline uses strand-aware RNA-seq 496

497 quantification, and the eQTLs were called using SusieR package 53 instead of FastQTL,

498 with expression PCs (selected with the elbow method) replacing PEER factors in the 499 modeling, and using the GENCODE v43 gene model (Supplementary File Table 2). 500 The pipeline natively generated credible sets with a set probability to contain a SNP 501 tagging the causal variant. **504 DATA AVAILABILITY** 506 The full set of GWAS summary statistics can be made available to qualified 507 investigators upon request and signing agreement with 23andMe to protect participant 508 confidentiality. The information can be accessed at 509 https://research.23andme.com/covid19-dataset-access/

530 REFERENCES

- 531
- 532 1. Mao, R. et al. Manifestations and prognosis of gastrointestinal and liver involvement in
- patients with COVID-19: a systematic review and meta-analysis. *Lancet Gastroenterol*.
- 534 Hepatol. 5, 667–678 (2020).
- 535 2. Parasa, S. et al. Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in
- Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. *JAMA*
- 537 Netw. Open 3, e2011335 (2020).
- 538 3. Sultan, S. et al. AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations
- of COVID-19, Meta-Analysis of International Data, and Recommendations for the
- Consultative Management of Patients with COVID-19. *Gastroenterology* **159**, 320-334.e27
- 541 (2020).
- 542 4. Nardo, A. D. et al. Pathophysiological mechanisms of liver injury in COVID-19. Liver Int. Off.
- 543 J. Int. Assoc. Study Liver **41**, 20–32 (2021).
- 544 5. Lin, L. et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut 69,
- 545 997–1001 (2020).
- 546 6. Xu, E., Xie, Y. & Al-Aly, Z. Long-term gastrointestinal outcomes of COVID-19. *Nat. Commun.*
- **14**, 983 (2023).
- 548 7. Natarajan, A. et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA
- suggest prolonged gastrointestinal infection. Med N. Y. N 3, 371-387.e9 (2022).
- 550 8. Hoffmann, M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is
- Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280.e8 (2020).
- 552 9. Hamming, I. et al. Tissue distribution of ACE2 protein, the functional receptor for SARS
- coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 203, 631–637
- 554 (2004).
- 555 10. Zollner, A. et al. Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in

- Inflammatory Bowel Diseases. *Gastroenterology* **163**, 495-506.e8 (2022).
- 557 11. Stein, S. R. et al. SARS-CoV-2 infection and persistence in the human body and brain at
- 558 autopsy. *Nature* **612**, 758–763 (2022).
- 559 12. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human
- tissues. *Science* **369**, 1318–1330 (2020).
- 561 13. Ma, D. et al. Single-cell RNA sequencing identify SDCBP in ACE2-positive bronchial
- epithelial cells negatively correlates with COVID-19 severity. J. Cell. Mol. Med. 25,
- 563 7001–7012 (2021).
- 14. Downes, D. J. et al. Identification of LZTFL1 as a candidate effector gene at a COVID-19
- risk locus. *Nat. Genet.* **53**, 1606–1615 (2021).
- 566 15. Qiu, C. et al. Renal compartment-specific genetic variation analyses identify new pathways
- in chronic kidney disease. *Nat. Med.* **24**, 1721–1731 (2018).
- 568 16. Kettunen, J. et al. Genome-wide association study identifies multiple loci influencing human
- serum metabolite levels. *Nat. Genet.* **44**, 269–276 (2012).
- 570 17. Franzén, O. et al. Cardiometabolic risk loci share downstream cis- and trans-gene
- regulation across tissues and diseases. *Science* **353**, 827–830 (2016).
- 572 18. Raj, T. et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in
- leukocytes. *Science* **344**, 519–523 (2014).
- 574 19. Zhang, J. et al. Plasma proteome analyses in individuals of European and African ancestry
- identify cis-pQTLs and models for proteome-wide association studies. Nat. Genet. 54,
- 576 593–602 (2022).
- 577 20. Ferkingstad, E. et al. Large-scale integration of the plasma proteome with genetics and
- 578 disease. *Nat. Genet.* **53**, 1712–1721 (2021).
- 579 21. Orho-Melander, M. et al. Common missense variant in the glucokinase regulatory protein
- gene is associated with increased plasma triglyceride and C-reactive protein but lower
- fasting glucose concentrations. *Diabetes* **57**, 3112–3121 (2008).

- 582 22. Chiang, J. Y. L. & Ferrell, J. M. Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in
- bile acid synthesis. *Liver Res.* **4**, 47–63 (2020).
- 584 23. Pathak, M. & Lal, G. The Regulatory Function of CCR9+ Dendritic Cells in Inflammation and
- 585 Autoimmunity. *Front. Immunol.* **11**, 536326 (2020).
- 586 24. Severe Covid-19 GWAS Group et al. Genomewide Association Study of Severe Covid-19
- with Respiratory Failure. N. Engl. J. Med. 383, 1522–1534 (2020).
- 588 25. Shelton, J. F. et al. Trans-ancestry analysis reveals genetic and nongenetic associations
- with COVID-19 susceptibility and severity. *Nat. Genet.* **53**, 801–808 (2021).
- 590 26. COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19.
- 591 Nature **600**, 472–477 (2021).
- 592 27. Uehara, S., Grinberg, A., Farber, J. M. & Love, P. E. A role for CCR9 in T lymphocyte
- development and migration. *J. Immunol. Baltim. Md* 1950 **168**, 2811–2819 (2002).
- 594 28. Menees, S. & Chey, W. The gut microbiome and irritable bowel syndrome. F1000Research
- **7**, F1000 Faculty Rev-1029 (2018).
- 596 29. Wang, B. et al. Alterations in microbiota of patients with COVID-19: potential mechanisms
- and therapeutic interventions. Signal Transduct. Target. Ther. 7, 143 (2022).
- 598 30. Dupuis, J. et al. New genetic loci implicated in fasting glucose homeostasis and their impact
- on type 2 diabetes risk. *Nat. Genet.* **42**, 105–116 (2010).
- 600 31. Kim, Y. K. et al. Identification of a genetic variant at 2q12.1 associated with blood pressure
- in East Asians by genome-wide scan including gene-environment interactions. BMC Med.
- 602 Genet. 15, 65 (2014).
- 603 32. Ma, M., Lee, J. H. & Kim, M. Identification of a TMEM182 rs141764639 polymorphism
- associated with central obesity by regulating tumor necrosis factor-α in a Korean population.
- J. Diabetes Complications **34**, 107732 (2020).
- 606 33. Cochet-Bissuel, M., Lory, P. & Monteil, A. The sodium leak channel, NALCN, in health and
- disease. Front. Cell. Neurosci. 8, 132 (2014).

- 608 34. Bourque, D. K. et al. Periodic breathing in patients with NALCN mutations. J. Hum. Genet.
- **609 63**, 1093–1096 (2018).
- 610 35. Moloney, D. J. et al. Fringe is a glycosyltransferase that modifies Notch. Nature 406,
- 611 369–375 (2000).
- 612 36. Zhou, B. et al. Notch signaling pathway: architecture, disease, and therapeutics. Signal
- 613 Transduct. Target. Ther. 7, 95 (2022).
- 614 37. Del Castillo Velasco-Herrera, M. et al. Comparative genomics reveals that loss of lunatic
- fringe (LFNG) promotes melanoma metastasis. *Mol. Oncol.* **12**, 239–255 (2018).
- 616 38. Shelton, J. F. et al. The UGT2A1/UGT2A2 locus is associated with COVID-19-related loss of
- smell or taste. *Nat. Genet.* **54**, 121–124 (2022).
- 618 39. Durand, E. Y., Do, C. B., Mountain, J. L. & Macpherson, J. M. Ancestry Composition: A
- Novel, Efficient Pipeline for Ancestry Deconvolution.
- 620 http://biorxiv.org/lookup/doi/10.1101/010512 (2014) doi:10.1101/010512.
- 621 40. Wellcome Trust Case Control Consortium et al. Bayesian refinement of association signals
- for 14 loci in 3 common diseases. *Nat. Genet.* **44**, 1294–1301 (2012).
- 623 41. Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in
- 624 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
- Estimator. *Genet. Epidemiol.* **40**, 304–314 (2016).
- 626 42. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
- instruments: effect estimation and bias detection through Egger regression. Int. J.
- 628 Epidemiol. 44, 512–525 (2015).
- 629 43. Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between
- imprecisely measured traits using GWAS summary data. *PLoS Genet.* **13**, e1007081
- 631 (2017).
- 632 44. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).
- 633 45. Kerimov, N. et al. A compendium of uniformly processed human gene expression and

- splicing quantitative trait loci. *Nat. Genet.* **53**, 1290–1299 (2021).
- 635 46. Lappalainen, T. et al. Transcriptome and genome sequencing uncovers functional variation
- in humans. *Nature* **501**, 506–511 (2013).
- 637 47. Koolpe, G. A. et al. Opioid agonists and antagonists. 6-Desoxy-6-substituted lactone,
- epoxide, and glycidate ester derivatives of naltrexone and oxymorphone. J. Med. Chem. 28,
- 639 949–957 (1985).
- 640 48. Craig, D. W. et al. RNA sequencing of whole blood reveals early alterations in immune cells
- and gene expression in Parkinson's disease. *Nat. Aging* 1, 734–747 (2021).
- 642 49. Ongen, H., Buil, A., Brown, A. A., Dermitzakis, E. T. & Delaneau, O. Fast and efficient QTL
- mapper for thousands of molecular phenotypes. *Bioinformatics* **32**, 1479–1485 (2016).
- 644 50. Stegle, O., Parts, L., Piipari, M., Winn, J. & Durbin, R. Using probabilistic estimation of
- expression residuals (PEER) to obtain increased power and interpretability of gene
- expression analyses. *Nat. Protoc.* **7**, 500–507 (2012).
- 647 51. Storey, J. D. A Direct Approach to False Discovery Rates. J. R. Stat. Soc. Ser. B Stat.
- 648 Methodol. 64, 479–498 (2002).
- 649 52. Harrow, J. et al. GENCODE: the reference human genome annotation for The ENCODE
- 650 Project. Genome Res. 22, 1760–1774 (2012).
- 651 53. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A Simple New Approach to Variable
- Selection in Regression, with Application to Genetic Fine Mapping. J. R. Stat. Soc. Ser. B
- 653 Stat. Methodol. 82, 1273–1300 (2020).

654

655

656

657

659 ACKNOWLEDGEMENTS 660 661 We thank the 23andMe research participants and employees who made this study 662 possible. The following members of the 23andMe Research Team contributed to this 663 study: 664 Stella Aslibekyan, Adam Auton, Elizabeth Babalola, Robert K. Bell, Jessica Bielenberg, 665 Jonathan Bowes, Katarzyna Bryc, Ninad S. Chaudhary, Daniella Coker, Sayantan Das, 666 Emily DelloRusso, Sarah L. Elson, Nicholas Eriksson, Teresa Filshtein, Pierre 667 Fontanillas, Will Freyman, Zach Fuller, Chris German, Julie M. Granka, Karl Heilbron, 668 Alejandro Hernandez, Barry Hicks, David A. Hinds, Ethan M. Jewett, Yunxuan Jiang, 669 Katelyn Kukar, Alan Kwong, Yanyu Liang, Keng-Han Lin, Bianca A. Llamas, Matthew H. 670 McIntyre, Steven J. Micheletti, Meghan E. Moreno, Priyanka Nandakumar, Dominique T. 671 Nguyen, Jared O'Connell, Aaron A. Petrakovitz, G. David Poznik, Alexandra Revnoso, 672 Shubham Saini, Morgan Schumacher, Leah Selcer, Anjali J. Shastri, Janie F. Shelton, 673 Jingchunzi Shi, Suyash Shringarpure, Qiaojuan Jane Su, Susana A. Tat, Vinh Tran, 674 Joyce Y. Tung, Xin Wang, Wei Wang, Catherine H. Weldon, Peter Wilton, Corinna D. 675 Wong. 676 677 678 679 680 681 682 683 684 685


```
687 AUTHOR INFORMATION
688
689 Affiliations:
690
691 23andMe, Inc:
692
693 Ninad S. Chaudhary, Catherine H. Weldon, Priyanka Nandakumar,
694 23andMe Research Team, Michael V. Holmes, Stella Aslibekyan
695
696 Bristol Myers Squibb, Inc:
697
698 Janie F. Shelton
699
700
701 Author Contributions
702
703 The 23andMe COVID-19 Team developed the recruitment and participant engagement
704 strategy and acquired and processed the data. N.S.C analyzed the data. N.S.C., P.A,
705 C.H.W, S.A, and M.V.H interpreted the data. N.S.C., S.A. and M.V.H. wrote the
706 manuscript. All authors participated in the preparation of the manuscript by reading and
707 commenting on the drafts before submission.
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
```

725 ETHICS DECLARATIONS 727 Competing Interests 729 C.H.W, P.N, S,A, and M.V.H are current employees of 23andMe and hold stock or stock 730 options in 23andMe. J.S is a current employee of Bristol Myers Squibb. N.S.C works as 731 a postdoctoral fellow on the 23andMe Genetic Epidemiology Team.

763 FIGURE LEGENDS

765 Figure 1 : Manhattan plot of COVID-19+ diarrhea among 23andMe participants 766 who tested positive for SARS-CoV2

767 Manhattan plot depicts findings from meta-analysis of five ancestral groups (European, 768 African, Latinx, East Asian, and South Asian). X-axis represents chromosomal position 769 for each SNP. Y-axis represents negative log p values based on logistic regression 770 model under the additive model. Statistically significant variants are highlighted in red. 771 The regions of associations are annotated with index variants.



788 Figure 2: Phenome-wide association of GWAS significant hits of COVID-19+789 diarrhea in 23andMe participants of European ancestry

790 Forest plot represents statistically significant findings from PheWAS analysis of four loci.

791 The results are presented as odds ratio and 95% confidence intervals under additive

792 model for allele of each loci to represent increased odds of having COVID-19+ diarrhea.

793 X-axis shows estimates on log scale. Y-axis shows phenotypes studied. We have

794 included gastrointestinal phenotypes from PheWAS analysis that met the statistically

795 significant threshold of 5.62 X 10⁻⁰⁶. A complete list of phenotypes that met statistical

796 threshold are included in Supplementary Table 5.





Figure 3: Forest plot representing genetically predicted effects of irritable bowel syndrome subtypes on COVID-19+ diarrhea using Mendelian randomization
The estimates in the plot depict odds ratio and 95% confidence intervals. IBS-C = lrritable bowel syndrome subtype constipation, IBS-D = Irritable bowel syndrome subtype diarrhea, IVW = Inverse variance weighted. The genetic instrument for IBS-C is derived using information from 50 SNPs (meanF statistic = 44.1) and genetic instrument for IBS-D is derived using information from 213 SNPs (meanF statistic = 49.5).



Characteristics	COVID-19+ diarrhea	COVID-19+ without diarrhea	
No	80,289	159,577	
Demographics			
Age mean (SD)	43.23 (14.12)	44.11 (15.10)	
Female N (%)	57,065 (71.1)	104,329 (65.4)	
Education in years mean (SD)	15.06 (2.37)	15.34 (2.47)	
Ancestry N (%)			
African American	3297 (4.1)	7179 (4.5) 3047 (1.9) 120470 (75.5) 27656 (17.3)	
East Asian	1282 (1.6)		
European	59821 (74.5)		
Latinx	15508 (19.3)		
South Asian	381 (0.5)	1225 (0.8)	
BMI mean (SD)	30.05 (7.55)	28.55 (6.82)	
Tobacco Use N (%)	30,091 (38.5)	53,654 (34.5)	
Two or more alcohol drinks per week – current N (%)	6,398(23.0)	33,544(23.2)	
Health Comorbidities			
High blood pressure N (%)	20,363 (25.8)	34,836 (22.2)	
Depression N (%)	32,418 (44.5)	50,773 (34.9)	
Diabetes N (%)	10,477 (14.1)	16,083 (10.9)	
High total cholesterol N (%)	5679 (19.1)	10371 (16.8)	
High triglycerides N (%)	4277 (26.3)	7194 (21.1)	
COVID-19+ related characteristics			

Table 1. Characteristics of 239,866 research participants in 23andMe COVID-19+ study					
Characteristics	COVID-19+ diarrhea	COVID-19+ without diarrhea			
COVID-19+ and severe respiratory disease N (%)	8,170 (10.2)	7,702 (4.8)			

SD=standard deviation, IQR=Interquartile-range, COPD=Chronic Obstructive Pulmonary Disease, BMI=Body-Mass Index, Severe respiratory disease= pneumonia, difficulty breathing that may have required supplementary oxygen, or ventilatory support

SNP	Chr	Position	Alleles	Gene	Effect allele	EAF	OR(95%CI)	P value
rs10504255	chr8	58485902	A/G	UBXN2B[]-CYP7A1	G	0.344	0.94(0.92,0.95)	2.56X10 ⁻¹⁶
rs35044562	chr3	45867532	A/G	LZTFL1[]CCR9	G	0.078	1.10(1.07,1.13)	4.88X10 ⁻¹³
rs75683620	chr2	103792340	A/G	TMEM182[]	G	0.9991	0.67(0.59,0.77)	5.04X10 ⁻⁰⁹
rs536843010	chr13	101100662	A/C	[NALCN]	С	0.991	0.81(0.75,0.87)	9.82X10 ⁻⁰⁹
rs13245319	chr7	2514631	C/T	GRIFIN[]-LFNG	Т	0.021	1.16(1.10,1.22)	1.79X10 ⁻⁰⁸
rs1260326	chr2	27508073	C/T	[GCKR]	Т	0.416	1.04(1.03,1.05)	1.98X10 ⁻⁰⁸